MODD
Modular Medical, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
3.53
▲ 0.10 (2.92%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
3.69
Prev close
3.43
Day high
3.58
Day low
3.24
Volume
69.79K
Market cap
$28.85M
P/E (TTM)
—
52W range
1.72 – 30.00
Day trading desk
Gap from prior close
+7.58%
Prior close 3.43
VWAP
3.48
+1.32% from price
Relative volume
0.32×
Quiet session
Session range
34.39%
3.14 – 4.22
Position in range
36%
Mid range
ATR (14D)
0.41
11.63% of price
Prior day high
3.75
PDH
Prior day low
3.16
PDL
Bid / ask spread
—
Quote not published
Session volume
70.24K
Avg 221.92K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+42.17%
+43.5%
1M
+16.45%
+12.7%
3M
-14.70%
-17.8%
6M
-76.02%
-87.1%
YTD
-67.58%
-79.9%
1Y
-83.38%
-103.4%
3Y
-87.96%
-162.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MODD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-1.24M
Net selling
Buy transactions
105
5.98M shares
Sell transactions
1
7.22M shares
Net transactions
+106
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
138.07K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 30, 26 | FELSHER STEVEN G Director |
STOCK | 25 | $0 | Direct |
| Jun 30, 26 | DESISTO DUANE M Director |
STOCK | 83 | $0 | Direct |
| Jun 30, 26 | VOLKART CARMEN B Director |
STOCK | 110 | $0 | Direct |
| Mar 31, 26 | FELSHER STEVEN G Director |
STOCK | 25 | $0 | Direct |
| Mar 31, 26 | DESISTO DUANE M Director |
STOCK | 83 | $0 | Direct |
| Mar 31, 26 | VOLKART CARMEN B Director |
STOCK | 103 | $0 | Direct |
| Dec 31, 25 | FELSHER STEVEN G Director |
— | 750 | — | Direct |
| Dec 31, 25 | DESISTO DUANE M Director |
— | 2.50K | — | Direct |
| Dec 31, 25 | VOLKART CARMEN B Director |
— | 3.13K | — | Direct |
| Dec 11, 25 | FELSHER STEVEN G Director |
— | 60.00K | — | Direct |
| Dec 11, 25 | SHEIBLEY PHILIP BRENT Director |
— | 22.00K | — | Direct |
| Sep 30, 25 | FELSHER STEVEN G Director |
— | 750 | — | Direct |
| Sep 30, 25 | DESISTO DUANE M Director |
— | 2.50K | — | Direct |
| Sep 30, 25 | VOLKART CARMEN B Director |
— | 3.13K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DESISTO DUANE M |
Director | 8.63K | Stock Award(Grant) |
FELSHER STEVEN G |
Director | 8.50K | Stock Award(Grant) |
MANCHESTER MANAGEMENT CO L L C |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SHEIBLEY PHILIP BRENT |
Director | 97.51K | Stock Award(Grant) |
VOLKART CARMEN B |
Director | 916 | Stock Award(Grant) |
Fundamentals
Market cap$28.85M
Enterprise value$25.21M
Revenue (TTM)—
Gross profit—
EBITDA$-25.53M
Net income$-28.03M
EPS (TTM)$-9.85
Free cash flow$-17.97M
Total cash$3.92M
Total debt$278.00K
Book value / share$2.78
Shares outstanding8.15M
Float6.64M
Short % of float3.57%
Dividend yield—
Beta (5Y)0.16
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.94
PEG ratio—
Price / sales—
Price / book1.27
EV / revenue—
EV / EBITDA-0.99
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-247.94%
Return on assets-129.12%
Debt / equity2.58
Current ratio3.25
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | — | — |
| Research & development | $19.97M | $14.70M | $12.88M | $9.06M | — | +35.9% |
| Selling, general & admin | $7.59M | $4.35M | $4.65M | $4.82M | — | +74.4% |
| Total operating expense | $27.56M | $19.05M | $17.53M | $13.88M | — | +44.7% |
| Operating income | -$27.56M | -$19.05M | -$17.53M | -$13.88M | — | -44.7% |
| Net interest income | — | — | — | $0 | -$2.75M | — |
| Pre-tax income | -$28.24M | -$18.82M | -$17.47M | -$13.88M | — | -50.0% |
| Tax provision | $2.00K | $2.00K | $2.00K | $2.00K | — | 0.0% |
| Net income | -$28.24M | -$18.82M | -$17.47M | -$13.88M | — | -50.0% |
| Net income to common | -$28.24M | -$18.82M | -$17.47M | -$13.88M | — | -50.0% |
| Basic EPS | -12.36 | -15.26 | -23.40 | -34.50 | — | +19.0% |
| Diluted EPS | -12.36 | -15.26 | -23.40 | -34.50 | — | +19.0% |
| EBIT | -$27.56M | -$19.05M | -$17.53M | -$13.88M | — | -44.7% |
| EBITDA | -$25.89M | -$17.98M | -$17.10M | -$13.73M | — | -43.9% |
| Basic shares | 2.29M | 1.23M | 745.90K | 403.43K | — | +85.3% |
| Diluted shares | 2.29M | 1.23M | 745.90K | 403.43K | — | +85.3% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.94M | $13.10M | $9.23M | $3.80M | -47.0% |
| Cash & short-term investments | $6.94M | $13.10M | $9.23M | $3.80M | -47.0% |
| Total current assets | $7.54M | $13.52M | $9.70M | $4.05M | -44.2% |
| Property, plant & equipment | $7.23M | $5.22M | $4.11M | $3.20M | +38.5% |
| Total assets | $14.83M | $18.73M | $13.81M | $7.25M | -20.8% |
| Total current liabilities | $1.87M | $1.26M | $1.46M | $979.00K | +48.1% |
| Total debt | $393.00K | $816.00K | $1.19M | $1.54M | -51.8% |
| Total liabilities | $1.87M | $1.66M | $2.27M | $2.17M | +13.0% |
| Retained earnings | -$113.00M | -$84.75M | -$65.93M | -$48.46M | -33.3% |
| Shareholder equity | $12.96M | $17.08M | $11.54M | $5.08M | -24.1% |
| Working capital | $5.67M | $12.25M | $8.24M | $3.07M | -53.7% |
| Net tangible assets | $12.96M | $17.08M | $11.54M | $5.08M | -24.1% |
| Shares issued | 4.66M | 1.79M | 1.08M | 364.98K | +160.4% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$28.24M | -$18.82M | -$17.47M | -$13.88M | -50.0% |
| Depreciation & amortisation | $1.67M | $1.06M | $426.00K | $152.00K | +57.3% |
| Stock-based compensation | $1.78M | $2.38M | $2.70M | $2.72M | -25.3% |
| Change in working capital | $194.00K | -$392.00K | $351.00K | -$211.00K | +149.5% |
| Operating cash flow | -$23.75M | -$15.72M | -$13.95M | -$11.01M | -51.1% |
| Capital expenditure | -$3.93M | -$2.49M | -$1.70M | -$1.64M | -57.7% |
| Investing cash flow | -$3.93M | -$2.49M | -$1.70M | -$1.64M | -57.7% |
| Financing cash flow | $21.53M | $22.08M | $21.09M | $7.37M | -2.5% |
| Free cash flow | -$27.68M | -$18.21M | -$15.65M | -$12.65M | -52.0% |
| End cash position | $6.94M | $13.10M | $9.23M | $3.80M | -47.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.84M | $5.41M | $5.59M | $5.13M | $3.94M | — | -28.9% |
| Selling, general & admin | $1.84M | $1.84M | $2.24M | $1.67M | $1.04M | — | +0.2% |
| Total operating expense | $5.68M | $7.24M | $7.83M | $6.80M | $4.98M | — | -21.5% |
| Operating income | -$5.68M | -$7.24M | -$7.83M | -$6.80M | -$4.98M | — | +21.5% |
| Pre-tax income | -$6.39M | -$7.36M | -$7.79M | -$6.70M | -$4.93M | — | +13.2% |
| Tax provision | $0 | $0 | $2.00K | — | $0 | $0 | — |
| Net income | -$6.39M | -$7.36M | -$7.79M | -$6.70M | -$4.93M | — | +13.2% |
| Net income to common | -$6.39M | -$7.36M | -$7.79M | -$6.70M | -$4.93M | — | +13.2% |
| Basic EPS | — | -3.30 | -4.20 | -3.60 | — | -3.90 | — |
| Diluted EPS | — | -3.30 | -4.20 | -3.60 | — | -3.90 | — |
| EBIT | -$5.68M | -$7.24M | -$7.83M | -$6.80M | -$4.98M | — | +21.5% |
| EBITDA | -$5.24M | -$6.81M | -$7.44M | -$6.39M | -$4.65M | — | +23.1% |
| Basic shares | — | 2.20M | 1.85M | 1.81M | — | 1.26M | — |
| Diluted shares | — | 2.20M | 1.85M | 1.81M | — | 1.26M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.94M | $2.94M | $5.32M | $7.52M | $13.10M | +136.4% |
| Cash & short-term investments | $6.94M | $2.94M | $5.32M | $7.52M | $13.10M | +136.4% |
| Total current assets | $7.54M | $3.47M | $5.95M | $8.29M | $13.52M | +117.6% |
| Property, plant & equipment | $7.23M | $6.79M | $7.03M | $5.88M | $5.22M | +6.4% |
| Total assets | $14.83M | $10.26M | $12.97M | $14.17M | $18.73M | +44.6% |
| Total current liabilities | $1.87M | $2.18M | $4.04M | $2.05M | $1.26M | -14.0% |
| Total debt | $393.00K | $504.00K | $611.00K | $715.00K | $816.00K | -22.0% |
| Total liabilities | $1.87M | $4.38M | $4.21M | $2.33M | $1.66M | -57.2% |
| Retained earnings | -$113.00M | -$106.61M | -$99.25M | -$91.45M | -$84.75M | -6.0% |
| Shareholder equity | $12.96M | $5.88M | $8.77M | $11.84M | $17.08M | +120.4% |
| Working capital | $5.67M | $1.29M | $1.90M | $6.24M | $12.25M | +340.5% |
| Net tangible assets | $12.96M | $5.88M | $8.77M | $11.84M | $17.08M | +120.4% |
| Shares issued | 4.66M | 2.59M | 2.04M | 1.84M | 1.79M | +80.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$6.39M | -$7.36M | -$7.79M | -$6.70M | -$4.93M | +13.2% |
| Depreciation & amortisation | $441.00K | $430.00K | $391.00K | $410.00K | $326.00K | +2.6% |
| Stock-based compensation | -$293.00K | $534.00K | $813.00K | $724.00K | $374.00K | -154.9% |
| Change in working capital | -$282.00K | -$891.00K | $1.17M | $194.00K | -$87.00K | +68.4% |
| Operating cash flow | -$5.82M | -$7.16M | -$5.41M | -$5.37M | -$4.31M | +18.7% |
| Capital expenditure | -$1.00M | -$1.22M | -$771.00K | -$934.00K | -$948.00K | +17.8% |
| Investing cash flow | -$1.00M | -$1.22M | -$771.00K | -$934.00K | -$948.00K | +17.8% |
| Financing cash flow | $10.82M | $6.00M | $3.98M | $733.00K | $11.37M | +80.5% |
| Free cash flow | -$6.82M | -$8.38M | -$6.18M | -$6.31M | -$5.26M | +18.6% |
| End cash position | $6.94M | $2.94M | $5.32M | $7.52M | $13.10M | +136.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Dec 2024 | -3.60 | -3.90 | -8.3% |
| Sep 2024 | -3.30 | -4.20 | -27.3% |
| Jun 2024 | -5.55 | -3.60 | +35.1% |
| Mar 2024 | -6.00 | -4.20 | +30.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.69%
Held by institutions28.08%
Institutions holding26
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.61
+35.07% from price
SMA 20
2.40
+47.67% from price
SMA 50
3.43
+3.11% from price
SMA 100
3.99
-11.46% from price
SMA 200
7.79
-54.53% from price
EMA 12
2.79
+26.42% from price
EMA 26
2.82
+25.16% from price
EMA 50
3.28
+7.73% from price
RSI (14)
62.2
Neutral
MACD (12,26,9)
-0.03
Hist 0.24
ATR (14)
0.41
11.60% of price
Realised vol 30D
177.0%
Annualised
Bollinger upper
3.39
20, 2σ
Bollinger lower
1.40
20, 2σ
50 / 200 cross
Death
3.43 vs 7.79
Trend bias
Below 200
-54.53%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.60
More volatile than market
Correlation to SPY
0.17
Largely independent
Realised vol 30D
177.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-91.8%
Peak to trough
Max drawdown 5Y
-98.8%
Peak to trough
ATR 14
0.41
11.60% of price
Beta (reported)
0.16
5Y monthly, from filing
Short interest
Shares short
188.52K
Prior 162.28K
Change vs prior
+16.2%
Shorts adding
% of float
3.57%
Normal
% of shares out
3.48%
Against total outstanding
Days to cover
1.3
Liquid
Float
6.64M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 21, 24 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| Sep 19, 23 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jun 30, 23 | Benchmark | MAINTAINED | Speculative Buy | Speculative Buy |
| May 19, 23 | Oppenheimer | MAINTAINED | — | Outperform |
| Jan 30, 23 | Benchmark | MAINTAINED | — | Speculative Buy |
| Apr 8, 22 | Lake Street | INITIATED | — | Buy |
| Mar 25, 22 | Benchmark | INITIATED | — | Speculative Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:30
Split dateMar 31, 2026
SEC filings
Periodic Financial Reports
10-Q · 2026-08-14
Offering Registrations
S-3 · 2026-08-05
Periodic Financial Reports
10-K · 2026-06-29
Corporate Changes & Voting Matters
8-K · 2026-05-20
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-01
Offering Registrations
S-3 · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-04-16
Corporate Changes & Voting Matters
8-K · 2026-03-31
Headlines
Modular Medical to Participate in the Association of Diabetes Care & Education Specialists 2026 Annual Conference
ACCESS Newswire · 18d ago
Modular Medical Announces Launch of Pivot Insulin Delivery System Across Five Key U.S. Markets Beginning October 2026
ACCESS Newswire · 20d ago
Modular Medical Announces Formation of Pivot Innovation Council and Appointment of Robert Gabbay, MD, PhD, FACP as Chairman
ACCESS Newswire · 31d ago
Modular Medical and IMO Health Launch Strategic Pilot to Enable Real Time Insulin Pump Patient Identification Into Electronic Health Records
ACCESS Newswire · 38d ago
Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump
ACCESS Newswire · 39d ago
Modular Medical Announces Completion of Research Initiative Indicating Strong Interest in Simpler Insulin Delivery
ACCESS Newswire · 40d ago
EXCLUSIVE: Modular Medical Advances Commercial Rollout With First Active Users Of Pivot Insulin Pump
Benzinga · 53d ago
Modular Medical Seeks FDA Clearance for Pivot Insulation Delivery System Enhancements
MT Newswires · 53d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.